Journal of Medicinal Chemistry

Addition/Correction

pubs.acs.org/jmc

Correction to Design of Bcl-2 and Bcl-xL Inhibitors with Subnanomolar Binding Affinities Based upon a New Scaffold

Haibin Zhou, Jianfang Chen, Jennifer L. Meagher, Chao-Yie Yang, Angelo Aguilar, Liu Liu, Longchuan Bai, Xin Cong, Qian Cai, Xueliang Fang, Jeanne A. Stuckey, and Shaomeng Wang*

Journal of Medicinal Chemistry **2012**, *55*, 4664−4682. DOI: 10.1021/jm300178

Page 4667. Figure 4A and Figure 4B were inadvertently interchanged. The correct Figure 4 is shown below. We acknowledge Dr. Asim K. Debnath for pointing out this error.



Figure 4. Structure-based design of a new scaffold as the initial lead compound **4** and its crystal structure in complex with Bcl-xL. (A, B) Rank 1 pose of (A) Lipitor and (B) Celecoxib with Bcl-xL, using the BAD BH3 peptide-bound Bcl-xL structure (PDB ID 2BZW). (C) Identification of the core scaffold from the FDA-approved drugs database for a new class of Bcl-2/Bcl-xL inhibitors. (D) Co-crystal structure of **4** in complex with Bcl-xL (1.7 Å).

Published: June 7, 2012